TherapeuticsMD (TherapeuticsMD) Interest Expense : $-0.12 Mil (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is TherapeuticsMD Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. TherapeuticsMD's interest expense for the three months ended in Dec. 2023 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.12 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. TherapeuticsMD's Operating Income for the three months ended in Dec. 2023 was $ -1.61 Mil. TherapeuticsMD's Interest Expense for the three months ended in Dec. 2023 was $ 0.00 Mil. GuruFocus does not calculate TherapeuticsMD's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

TherapeuticsMD Interest Expense Historical Data

The historical data trend for TherapeuticsMD's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TherapeuticsMD Interest Expense Chart

TherapeuticsMD Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-16.53

-26.05

-22.57

TherapeuticsMD Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-	-0.05	-0.05	-0.02	-

TherapeuticsMD Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.12 Mil.

TherapeuticsMD (NAS:TXMD) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

TherapeuticsMD's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-1.61 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $6.53 Mil.

TherapeuticsMD's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

GuruFocus does not calculate TherapeuticsMD's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

TherapeuticsMD (TherapeuticsMD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TherapeuticsMD Inc (NAS:TXMD) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

29TA:Germany

Address

951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431

Website

https://www.therapeuticsmd.com

TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.

Executives

Marlan D Walker	officer: General Counsel	951 YAMATO ROAD, SUITE 220, BOCA RATON FL 33431
Joseph Ziegler	officer: Principal Financial Officer	1051 HILLSBORO MILE, PH2, HILLSBORO BEACH FL 33062
Michael C Donegan	officer: CAO and VP of Finance	6800 BROKEN SOUND PARKWAY NW, THIRD FLOOR, BOCA RATON FL 33487-3507
Rubric Capital Management Lp	10 percent owner	155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Brian Bernick	director	951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Gail K Naughton	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Mark A Glickman	officer: Chief Business Officer	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Justin Hunter Roberts	director	C/O RUBRIC CAPTIAL MANAGEMENT LP, 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105
Karen Ling	director	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Paul Bisaro	director
Angus C. Russell	director	C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Jules A. Musing	director	9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
David Efraim Rosen	10 percent owner	155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Collins Cooper C.	director	33219 FOREST WEST DRIVE, MAGNOLIA TX 77354